Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Share-based Compensation (2016 - 2025)

Tg Therapeutics has reported Share-based Compensation over the past 10 years, most recently at $15.7 million for Q4 2025.

  • Quarterly results put Share-based Compensation at $15.7 million for Q4 2025, up 31.44% from a year ago — trailing twelve months through Dec 2025 was $64.6 million (up 53.67% YoY), and the annual figure for FY2025 was $64.7 million, up 52.16%.
  • Share-based Compensation for Q4 2025 was $15.7 million at Tg Therapeutics, down from $17.5 million in the prior quarter.
  • Over the last five years, Share-based Compensation for TGTX hit a ceiling of $36.5 million in Q4 2022 and a floor of -$1.0 million in Q2 2022.
  • Median Share-based Compensation over the past 5 years was $12.2 million (2023), compared with a mean of $12.5 million.
  • Biggest five-year swings in Share-based Compensation: tumbled 106.13% in 2022 and later soared 1350.0% in 2023.
  • Tg Therapeutics' Share-based Compensation stood at $14.4 million in 2021, then surged by 154.13% to $36.5 million in 2022, then crashed by 74.4% to $9.4 million in 2023, then grew by 27.32% to $11.9 million in 2024, then surged by 31.44% to $15.7 million in 2025.
  • The last three reported values for Share-based Compensation were $15.7 million (Q4 2025), $17.5 million (Q3 2025), and $16.4 million (Q2 2025) per Business Quant data.